Evidence map›Paper›PMID 42004689›Full record

ReviewThe journal of liquid biopsy2026

Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy.

Eloísa Jantus-Lewintre, Silvia Calabuig-Fariñas, David Gandara, Luis Raez, Natasha B Leighl, Nicola Fusco, Ola Khorshid, Clara Mayo de Las Casas, Carolina Reduzzi, Yuksel Urum and 4 more

Abstract readReview
In one paragraph

Review in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. The journal of liquid biopsy · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eloísa Jantus-LewintreInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain.
Silvia Calabuig-FariñasDepartment of Pathology, Universitat de Valéncia, Valencia, Spain.
David GandaraDeparment of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Luis RaezThoracic Oncology Program, Memorial Cancer Institute at Memorial Healthcare System, Florida Cancer Center of Excellence, Institute of Human Health and Disease Intervention, Florida Atlantic University (FAU), Miami, Florida, USA.
Natasha B LeighlDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Nicola FuscoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Ola KhorshidMedical Oncology Department NCI Cairo University, Cairo, Egypt.
Clara Mayo de Las CasasHospital Universitari Dexeus. Pangaea Oncology Laboratory, Barcelona, Spain.
Carolina ReduzziLiquid Biopsy Platform, Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
Yuksel UrumDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Charu AggarwalDivision of Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, USA.
Maria José SerranoDepartment of Pathology, Virgen de las Nieves University Hospital, IBS-Granada, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Christian RolfoDiane Nye and Michael Rayden Chair in Innovative Cancer Research, Division of Medical Oncology, OSUCCC-James, The Arthur G. James Comprehensive Cancer Center, Ohio, USA.
Umberto MalapelleDepartment of Public Health, University of Naples Federico II, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid expansion of liquid biopsy (LB) throughout the cancer care continuum is evidenced by the striking increase in annual publications, rising from approximately 100 per year in the early 2000s to more than 2200 in recent years. This exponential growth reflects the accelerating impact of LB across precision medicine. However, the field's evolution has been accompanied by inconsistent use of key terminology, creating barriers to clear communication, comparability of results, and appropriate clinical translation. To address this challenge, the International Society of Liquid Biopsy (ISLB) presents a comprehensive and harmonized terminology framework, an essential and timely effort to support the coherent advancement of the LB discipline. ISLB defines LB as the analysis of cells, nucleic acids, proteins, metabolites, and extracellular vesicles used to interrogate pathological or specific physiological conditions, obtained from bodily fluids, primarily through minimally invasive methods. Here we discuss relevant biospecimens, emphasizing their distinct sources and molecular characteristics. A central component of the manuscript is a rigorous clarification of analyte-specific terminology. This includes circulating free DNA and RNA (cfDNA, cfRNA), circulating tumor DNA and RNA (ctDNA, ctRNA), tumor fraction (TF), variant allele frequency (VAF), circulating tumor cells (CTCs), disseminated tumor cells (DTCs), circulating tumor microemboli (CTMs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), soluble proteins, and metabolomic signatures. The manuscript also outlines the analytical methodologies, that enable sensitive detection of low-abundance tumor-derived signals. Clinical applications of LB in Oncology are defined across the disease continuum, including early cancer detection, molecular residual disease (MoRD) assessment, predictive biomarker evaluation, and tumor monitoring. By establishing a cohesive vocabulary, ISLB provides a robust reference framework that will evolve with scientific progress and guide the integration of LB into precision medicine.

Indexed as

Circulating tumor cells (CTCs)Circulating tumor DNA (ctDNA)Early cancer detectionExtracellular vesiclesHarmonized definitionsLiquid biopsyMolecular residual disease (MoRD)Precision oncologyTerminology frameworkTumor fractionVariant allele frequency

Identifiers

PMID42004689
PMCPMC13087574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.